PharmaTimes Magazine

PharmaTimes is the UK's leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.

PharmaTimes print and digital versions have a total circulation of 23,184, reaching right across the industry into every company and every function. What's more, our circulation includes 8,000 NHS healthcare professionals: chief pharmacists, medicines management and primary care commissioners.

Click to subscribe to PharmaTimes in paper or print, or to sign up for our industry-leading daily and weekly news elerts.

You can read the latest issue as well as our extensive archive below or get in touch with the editorial or sales team.

Magazine highlights

View more from the latest edition
Thumbnail image for Divided opinion

Divided opinion

Amgen v Sanofi: narrowing the scope of protection for antibody inventions?

MAGAZINE EXCLUSIVE
Thumbnail image for Supply chain security

Supply chain security

Is blockchain the answer to protecting against counterfeits and medicines shortages?

MAGAZINE EXCLUSIVE
Thumbnail image for SMART PEOPLE: Jenny Ousbey

SMART PEOPLE: Jenny Ousbey

OVID Health founder Jenny Ousbey discusses the pandemic, patient advocacy and the Patient Partnership Index

Thumbnail image for HIV: the fight continues

HIV: the fight continues

Gilead Sciences’ global patient engagement lead and former HIV nurse specialist Geraldine Reilly explores today’s fight against the virus – as TV series It’s A Sin brings back memories of working on the frontline during the AIDS epidemic of the 1980s and 1990s

Thumbnail image for Smart People: Dr Nick West

Smart People: Dr Nick West

Abbott’s Dr Nick West talks to PharmaTimes about going beyond intervention to improve the care of cardiovascular patients in the UK

Thumbnail image for The first fallout

The first fallout

Taking a look at the recent dispute between the EU Commission and AstraZeneca over the ins and outs of its contract, Stuart Evans, commercial litigation expert and partner at law firm BLM, examines what this could represent for EU/UK cross-border pharma relations

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download